General Information of Drug (ID: DMZ76NQ)

Drug Name
6-Phenylsulfanyl-9H-purine Drug Info
Synonyms
Purine, 6-(phenylthio)-; 6-(Phenylthio)purine; 1H-Purine, 6-(phenylthio)-; 5450-35-1; NSC 15746; UNII-3KH11DU8DY; 6-phenylsulfanyl-7H-purine; BRN 0013668; 3KH11DU8DY; AI3-52068; AC1Q4XUH; AC1L3TI0; 4-26-00-01985 (Beilstein Handbook Reference); 9H-Purine,6-(phenylthio)-; SCHEMBL796397; 6-(phenylsulfanyl)-7H-purine; CHEMBL175600; 9H-Purine, 6-(phenylthio)-; CTK5A1336; DTXSID20202908; NSC15746; ZINC13608565; NSC-15746; AKOS030562402
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
95065
CAS Number
CAS 5450-35-1
TTD Drug ID
DMZ76NQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ozagrel DMIGKA1 Xerophthalmia 5B55.Y Phase 4 [2]
Losmapimod DMIL37Z Acute coronary syndrome BA41 Phase 3 [2]
VX-702 DMKJDR6 Coronary artery disease BA80 Phase 2a [3]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [4]
Dilmapimod DMBYJ92 Acute lung injury NB32.3 Phase 2 [2]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [5]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [5]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [5]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [5]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Stress-activated protein kinase 2a (p38 alpha) TTQBR95 MK14_HUMAN Inhibitor [1]

References

1 Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
2 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
3 Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
4 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
5 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.